Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [3]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-20989 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- IFITM1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- A suggested positive control is NIH-3T3 cell lysate.
- Concentration
- 1 mg/mL
Submitted references Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD
Journal of virology 2020 Nov 9;94(23)
Journal of virology 2020 Nov 9;94(23)
Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD
bioRxiv : the preprint server for biology 2020 Jul 13;
bioRxiv : the preprint server for biology 2020 Jul 13;
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.
Ma W, Tummers B, van Esch EM, Goedemans R, Melief CJ, Meyers C, Boer JM, van der Burg SH
Frontiers in immunology 2016;7:496
Frontiers in immunology 2016;7:496
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of 3T3 cell lysate using a CD225/IFITM1 polyclonal antibody (Product # PA5-20989) at (A) 1 and (B) 2 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot analysis of IFITM1 in 3T3 cell lysate with IFITM1 Polyclonal Antibody (Product # PA5-20989) at (A) 1 and (B) 2 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Jurkat cells using a CD225/IFITM1 polyclonal antibody (Product # PA5-20989) at a 20 µg/mL dilution.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry of IFITM1 in Jurkat cells with IFITM1 Polyclonal Antibody (Product # PA5-20989) at 20 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescence of IFITM1 in Jurkat cells with IFITM1 Polyclonal Antibody (Product # PA5-20989) at 20 µg/mL.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunocytochemistry staining of Jurkat cells using a CD225/IFITM1 polyclonal antibody (Product # PA5-20989) at a 20 µg/mL dilution.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 High-risk HPV-infected KCs downregulate IFITM1 to suppress the expression of RARRES1 and to maintain proliferation . (A) Microarray gene expression values for IFITM1 in four independent uninfected KCs and four independent hrHPV + KCs represented in a box plot. * P < 0.05. (B) The expression level of IFITM1 in HVK#1, HVK#2, HVK16, and HPV16 determined by RT-qPCR. Gene expression was normalized against GAPDH mRNA levels. (C) The expression level of IFITM1 in KCs infected with mock or native HPV16 virions for 1 or 2 days, respectively. (D) Expression of IFITM1 in HPV16 + KCs transfected with control siRNA (siControl) or siRNA targeting HPV16 E2 (siE2) stimulated with or without 50 IU/ml IFNgamma and 50 ng/ml TNFalpha for 24 h. Gene expression was normalized against GAPDH mRNA levels and fold-change over non-stimulated siControl was calculated. * P < 0.05, **** P < 0.0001. (E, F) The expression of IFITM1 in undifferentiated KCs and HPV16 + KCs stimulated with 50 IU/ml IFNgamma and/or 50 ng/ml TNFalpha for 24 h. Gene expression was normalized against GAPDH mRNA levels and fold-changes over (E) control-stimulated undifferentiated KCs or over (F) control-stimulated HPV16 + KCs were calculated and depicted. (G) IFITM1 protein levels in KC and HPV16 + KC stimulated with 0, 100, or 1000 IU/ml IFNgamma, as measured by WB. beta-actin served as loading control. (H) IFITM1 expression in control and IFITM1 knockdown uninfected KCs as measured by RT-qPCR. Gene expression was normali
